Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Withdrawn1

Completed1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

withdrawn133%

completed133%

terminated133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

NCT02243124

withdrawnphase_2

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

NCT00967512

completedphase_2

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

NCT00074737

Clinical Trials (3)

Showing 3 of 3 trials

NCT02243124Phase 1

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Terminated

NCT00967512Phase 2

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Withdrawn

NCT00074737Phase 2

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3